^
Association details:
| Biomarker: | KRAS Q61 |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Koselugo (selumetinib) (MEK inhibitor) + dactolisib (RTB101) (mTOR inhibitor, PI3K inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas
Excerpt:
Cross-analysis of mice harboring xenografts from the same original tumor and treated with each of the different modalities revealed subgroups with preferential sensitivity to AZD6244 (12.5%), BEZ235 (35%), or AZD6244 + BEZ235 (42.5%); another subgroup (10%) showed equivalent response to any treatment....Thirty-two samples (67.6%) harbored a KRAS mutation: 22 (55%) in codon 12; 5 (12.5%) in codon 13; 1 (2.5%) in codon 61; and 4 (10%) in codon 146.
DOI:
10.1158/1078-0432.CCR-11-2683
